OBJECTIVES: Targeted therapeutics have become integral to many cancer regimens owing to their improved efficacy yet come with financial implications. Since cancer is the leading cause of mortality among Singaporeans, it is crucial that patients have access to novel therapeutics. Medishield Life (MSL) is a recent government initiative that aims to provide affordable healthcare to all Singaporeans regardless of their age, income or pre-existing health condition. This research aims to investigate the potential implications of evolving healthcare policies on patient accessibility to targeted therapeutics. METHODS: In-depth interviews were conducted with senior medical oncologists, ministry of health officers, medical social workers, insurers and cancer patients. RESULTS: Most stakeholders expressed some enthusiasm over the launch of MSL suggesting that it would provide increased healthcare coverage. However, concerns were raised on its proficiency as a stand-alone plan to cover the full cost of treatment. Half of Singaporeans have already subscribed to additional insurance plans (Integrated Shield Plans or IP), despite having to pay additional premiums. Since IP premiums increase with age as well as with ward type, insurers have agreed to introduce a standardised B1 plan in May 2016. This may serve as an upgrade for patients with MSL, or an additional option for patients who wish downgrade their current IP plan due to increased premiums. However, not all insurers have agreed to cover pre-existing illnesses for patients- one of the most important benefits of MSL. As subscribers begin to hedge their options, insurers are preparing for a significant number of patients to downgrade their IP plans. CONCLUSIONS: MSL is one step closer in providing improved universal healthcare coverage to all Singaporeans; however it may not be sufficient to cover full cost of targeted therapies. Long term affordability would be a key determinant of whether patients would choose to subscribe, maintain or downgrade their IP policies.